Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.

ABSTRACT:

Introduction

Pancreatic ductal adenocarcinoma (PDAC) has the highest mortality rate among all solid tumors. Tumorigenesis is promoted by the oncogene KRAS, and KRAS mutations are prevalent in patients with PDAC. Therefore, a comprehensive understanding of the interactions between KRAS mutations and PDAC may expediate the development of therapeutic strategies for reversing the progression of malignant tumors. Our study aims at establishing and validating a prediction model of KRAS mutations in patients with PDAC based on survival analysis and mRNA expression.

Methods

A total of 184 and 412 patients with PDAC from The Cancer Genome Atlas (TCGA) database and the International Cancer Genome Consortium (ICGC), respectively, were included in the study.

Results

After tumor m

SUBMITTER: Yang F 

PROVIDER: S-EPMC10805828 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature